Entera Bio Ltd.

Entera Bio Ltd.

NNASDAQ:ENTX
3.02
USD
-0.09
(-2.89%)
-0.41EPS
506.11MMarket Cap
Mar 26Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.06
0.02
0.02
0.02
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.5
-0.14
-1.31
-1.3
-0.89
-0.61
-0.47
-0.45
-0.31
-0.25
-0.25
-0.41
Free Cash Flow per Basic Share
-0.41
-0.37
-0.53
-1.24
-0.74
-0.58
-0.35
-0.44
-0.25
-0.18
-0.16
-0.22
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-2.25
-2.21
-2.76
0.88
0.67
0.36
0.78
0.41
0.29
0.21
0.28
1.58
Tangible Book Value per Share
-2.3
-2.27
-2.82
0.83
0.63
0.33
0.78
0.41
0.29
0.21
0.28
1.58
Basic Weighted Avg Shares
9
9
9
8
12
18
26
29
29
38
46
72
Sales/Revenue/Turnover
- -
- -
- -
1
- -
- -
1
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
-2,172.2
-4,853.39
-3,059.73
-2,139.58
-9,714.18
- -
-5,295.58
-27,450
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-4
-1
-11
-10
-11
-11
-12
-13
-9
-10
-11
-29
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-2,060.8
-4,574.15
-3,072.88
-2,134.33
-9,754.48
- -
-5,271.27
-27,235.71
- -
Working Capital
1
-5
10
9
11
7
22
12
10
8
13
274
LT Debt
8
5
4
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
-26
-25
-32
10
12
8
23
12
10
8
13
274
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-97.98
-115.46
-81.04
-76.17
-80.3
-103.34
-108.01
-20.33

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
47
49
174
Market Capitalization
52
87
506

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
12
19
276
Cash, Cash Equivalents & STI
4
11
266
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.29%
36.17%
62.14%
Free Cash Flow
14.31%
-3.03%
9.62%
Net Income, GAAP
77.37%
2.23%
19.89%
Sales/Revenue/Turnover
- -
- -
-76.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
-0.06
-0.08
-0.06
-0.25
2025
-0.06
-0.06
-0.07
-0.07
-0.25
2026
-0.07
-0.14
-0.11
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Miranda J. Toledano
Full Time Employees
22
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Kiryat Hadassah Minrav Building Jerusalem JM Israel 9112002
IPO Date
Jun 28, 2018
Business
Entera Bio Ltd. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of orally delivered large molecule therapeutics targeting unmet medical needs. The company’s core products include oral peptide and protein replacement therapies primarily based on its proprietary N-Tab platform, which enhances the stabilization and systemic absorption of peptides in the gastrointestinal tract. Key product candidates include EB613 and EB612, oral formulations of human parathyroid hormone (PTH 1-34) designed for the treatment of osteoporosis and hypoparathyroidism, respectively. Entera is also developing the first oral oxyntomodulin tablet for obesity treatment and an oral GLP-2 peptide tablet for rare malabsorption conditions like short bowel syndrome, in collaboration with OPKO Biologics. The company’s products focus on transforming therapies traditionally administered by injection into convenient once-daily oral tablets to improve patient adherence and outcomes. Entera Bio operates globally with headquarters in Jerusalem, Israel, and addresses chronic conditions with significant unmet medical demand in metabolic bone disease, endocrine disorders, obesity, and intestinal malabsorption. Founded in 2012, the company is driven by a team of industry experts in drug development and oral peptide delivery. Recent major developments include a strategic research collaboration with OPKO Biologics initiated in 2023 to develop oral peptide tablet formulations for obesity and intestinal malabsorption, leveraging OPKO’s proprietary long-acting peptides and Entera’s oral delivery technology. Throughout 2025, Entera has reported positive clinical data supporting its oral GLP-2 treatment for short bowel syndrome and EB613 for osteoporosis, highlighting progress in its development pipeline for oral peptide therapeutics. The company also attracted increased investment interest with a notable acquisition of shares by Knoll Capital Management in late 2024, reflecting growing confidence in its clinical and technological prospects. Entera Bio maintains a strong intellectual property position with numerous patents and pending applications related to its oral delivery platform and peptide formulations. Its business model focuses on innovative oral therapies to replace injectable treatments, targeting cost, convenience, and compliance challenges in healthcare. The company’s advances embody a strategic shift towards delivering first-in-class oral peptide therapeutics aimed at improving the standard of care for chronic diseases that conventionally rely on injectable biologics. This comprehensive profile outlines Entera Bio’s specialized biopharmaceutical activities, advanced product pipeline, recent strategic collaborations, and clinical progress as of late 2025. The company remains headquartered in Jerusalem, Israel, serving a global market with products designed to enhance patient quality of life through oral peptide therapeutic innovation.

Company News

  • Entera Announces Third Quarter 2026 Financial Results and Business Updates

  • Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors

  • Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting

  • Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting

  • Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise

  • Correction: Entera to Participate in Upcoming Fall Investor Conferences

  • Entera to Participate in Upcoming Fall Investor Conferences

  • Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

  • Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement

  • Entera Announces Second Quarter 2026 Financial Results and Business Updates

  • Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting

  • Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

  • Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

  • Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE

  • Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk

  • Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement

  • Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know

  • Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market

  • Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market

  • Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis